GlassScriptPhysician profile
Elizabeth Butler
NPI 1356316566
$16,893.51
in general payments reported to CMS, 2019-2025
33 companies · $60.61 in 2025
The $60.61 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,083 · 2020: $2,672 · 2021: $3,191 · 2022: $4,391 · 2023: $1,960 · 2024: $535 · 2025: $60.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,439.00 | 2019-2023 | Rinvoq, Skyrizi, Ubrelvy |
| Amgen INC. | $2,684.64 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Horizon Therapeutics Plc | $1,654.15 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $963.90 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $861.14 | 2019-2023 | Simponi Aria, Simponi, Stelara |
| Mallinckrodt Hospital Products INC. | $815.71 | 2020-2023 | Acthar |
| Glaxosmithkline, LLC. | $770.27 | 2019-2023 | Benlysta, Shingrix, Bexsero |
| Ucb, INC. | $624.30 | 2019-2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $568.29 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $562.90 | 2019-2022 | |
| Pfizer INC. | $508.72 | 2019-2023 | |
| Abiomed | $459.26 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $413.45 | 2021-2023 | Saphnelo |
| Genentech USA, INC. | $394.67 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $376.03 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $349.03 | 2019-2021 | |
| Sobi, INC | $223.83 | 2019-2022 | |
| Celgene Corporation | $210.80 | 2019 | |
| Medexus Pharma, INC. | $189.66 | 2019-2020 | |
| Abbott Laboratories | $136.26 | 2024 | Optis |
| Ani Pharmaceuticals, INC. | $128.00 | 2022-2023 | Purified Cortrophin Gel |
| Genzyme Corporation | $114.62 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $88.05 | 2022 | |
| Novo Nordisk INC | $77.62 | 2021-2023 | Rybelsus, Ozempic |
| Radius Health, INC. | $77.39 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $53.94 | 2019 | |
| Exact Sciences Corporation | $33.04 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $25.77 | 2020 | |
| Medtronic USA, INC. | $22.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.18 | 2019 | |
| Hologic Sales and Service, LLC | $16.48 | 2022 | |
| Fresenius Kabi USA, LLC | $15.42 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.